

Melanocortin Receptor 4 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/M099406F1BFDEN.html>

Date: October 2020

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: M099406F1BFDEN

Abstracts

Melanocortin Receptor 4 - Pipeline Review, H2 2020

SUMMARY

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome).

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC

filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

Aequus BioPharma Inc

Eton Pharmaceuticals Inc

LG Chem Ltd

Mallinckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

(liraglutide + setmelanotide hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-54640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LR-19021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-9610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Oct 20, 2020: City of Rockford \$10 billion lawsuit against pharmaceutical giant
Mallinckrodt threatened by bankruptcy

Sep 28, 2020: LG Chem's obesity treatment wins ODD status in US

Jul 16, 2020: Rhythm Pharmaceuticals announces publication of results from phase 2
study of Setmelanotide in Bardet-Biedl Syndrome in diabetes, obesity and metabolism

Jul 06, 2020: MC4R agonist (LB54640) Poster Presentation at ADA 2020

Jul 01, 2020: Rhythm Pharmaceuticals announces submission of Marketing
Authorization Application to the European Medicines Agency for setmelanotide in
POMC and LEPR deficiency obesities

Jul 01, 2020: Rhythm Pharmaceuticals receives rare pediatric disease designation from
U.S. Food and Drug Administration for setmelanotide for treatment of POMC and LEPR
deficiency obesities

Jun 24, 2020: Positive results from Phase 2 study of once-weekly FluidCrystal
formulation of setmelanotide in healthy volunteers with obesity

Jun 24, 2020: Rhythm Pharmaceuticals announces positive results from phase 2 study
of once-weekly formulation of setmelanotide in healthy obese volunteers

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision
denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with
the Centers for Medicare and Medicaid Services (CMS)

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision
denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with
the Centers for Medicare and Medicaid Services (CMS)

Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing
Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid
Services (CMS)

Jun 01, 2020: LG Chem Life Sciences Company receives FDA approval for IND
application of LB54640 for the treatment of genetic disorders of obesity

May 13, 2020: Rhythm Pharmaceuticals announces FDA acceptance of new drug
application for Setmelanotide for the treatment of POMC and LEPR deficiency obesities

Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository
Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4
study in rheumatoid arthritis (RA) in Rheumatology and Therapy

Mar 30, 2020: Rhythm Pharmaceuticals completes rolling submission of New Drug
Application to U.S. Food and Drug Administration for Setmelanotide in POMC and
LEPR deficiency obesities

Appendix

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aequus BioPharma Inc, H2 2020
Pipeline by Eton Pharmaceuticals Inc, H2 2020
Pipeline by LG Chem Ltd, H2 2020
Pipeline by Mallinckrodt Plc, H2 2020
Pipeline by Palatin Technologies Inc, H2 2020
Pipeline by Rhythm Pharmaceuticals Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Melanocortin Receptor 4 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/M099406F1BFDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M099406F1BFDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970